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This is the initial step in the metabolic cascade, leading to the synthesis of eicosanoids (prostaglandins, leukotrienes [LTs] , and other). PLA 2 s thought to play a role in arachidonic acid release are currently classified as high-molecular-weight cytosolic phospholipases A 2 (cPLA 2 s) and low-molecular-weight secreted PLA 2 s (sPLA 2 s). 1 Ten isoforms of sPLA 2 s have been identified in human cells and tissues. 2 sPLA 2 s are released in extracellular fluids during local or systemic inflammation. 3 In addition, it has been previously shown that sPLA 2 activity is detectable in the bronchoalveolar lavage fluid (BALF) of healthy individuals. 4 This activity is increased in the airways of patients with inflammatory lung diseases (pneumonia, adult respiratory distress syndrome, and sarcoidosis). 3 Moreover, sPLA 2 activity is also increased in the BALF of patients with bronchial asthma 5, 6 and in the nasal fluid of patients with allergic rhinitis after local allergen challenge. 7 These observations indicate that sPLA 2 enzymes can be released during allergic reactions in both the upper and lower airways. However, these studies did not provide information on the cellular sources of these enzymes.
The role of sPLA 2 isoforms in airway inflammation has been investigated in rodents. For example, several sPLA 2 s, such as GIIA, GIID, GIIE, GV, and GX, are overexpressed in lung biopsy specimens in experimentally induced pulmonary inflammation. 8, 9 In particular, GX, the isoform with the highest phospholipolytic activity in mammalian cells in vitro, 10, 11 is constitutively expressed in the lung. 8, 9 Interestingly, GX expression did not change on LPS-or carrageenin-induced lung inflammation, 8 whereas it was significantly increased in the airways of mice with ovalbumin-induced asthma. 9 Moreover, knocking out GX reduced all the histologic and functional features associated with the inflammatory response and airway remodeling in this model of asthma. These studies demonstrated that certain sPLA 2 s play an important role in the pathogenesis of inflammatory and allergic diseases of the lung.
The expression of sPLA 2 isoforms in the upper and lower airways has been examined in patients with chronic rhinosinusitis or pneumonia. 12, 13 Immunohistochemistry revealed that low levels of human GIIA (hGIIA) were expressed in the nasal epithelium and submucosal glands of healthy donors, whereas the expression of this sPLA 2 was increased in patients with rhinosinusitis. 12 In the lung only human GX (hGX) was detected in bronchial epithelial cells and subepithelial interstitium of both healthy donors and patients with pneumonia. 13 In inflamed, but not normal, lung tissue hGIIA was found in vascular smooth muscle cells and bronchial chondrocytes, whereas human GIID, GV, and GX were found in epithelial cells and macrophages. Immunostaining analysis of cells from induced sputum demonstrated that hGX was expressed by bronchial epithelial cells and macrophages in healthy donors and patients with asthma.
14 However, in asthmatic patients the expression of hGX was significantly higher than in healthy subjects and was further increased during exercise-induced bronchoconstriction. These observations indicate that sPLA 2 expression is upregulated in human airways during inflammatory and allergic disorders and suggest that cells resident in the lung might produce distinct sPLA 2 s.
Mast cells play a primary role in the pathogenesis of bronchial asthma and rhinitis. 15 These cells can be activated by IgE-and non-IgE-mediated stimuli to release a variety of preformed and de novo synthesized proinflammatory mediators. 16 Mast cells are particularly abundant at the body's interface with the external environment, such as the mucosae of the respiratory and gastrointestinal tracts and the skin. 17 This unique location justifies the important role of mast cells in allergic inflammation, as well as innate immunity and host defense against infections. [16] [17] [18] Studies on the expression of sPLA 2 s in mast cells have been primarily carried out in mice. Enomoto et al 19 showed that bone marrow-derived mast cells (BMMCs) from BALB/cJ and C57BL/6J mice express all members of the group II subfamily of sPLA 2 s, including GIIC, GIID, GIIE, GIIF, and GV. GIIA is expressed in BALB/cJ but not in C57BL/6J mast cells because the latter strain has a natural disruption of the gene encoding for GIIA. BMMCs from either strains do not express GIB and GX sPLA 2 s. 19 This and other studies 20 indicate that the expression pattern of sPLA 2 isoforms differs in mast cells with different phenotypes and from different animal species.
Marked biochemical and functional differences exist between murine and human mast cells, and in many cases information on cell activation and mediator production obtained in murine models was not confirmed in human mast cells. 21 Data on sPLA 2 expression in human mast cells are scarce because of the limited number of cells detectable in biopsy specimens or retrieved from biologic fluids. Immunohistochemistry studies demonstrated that human synovial 22 and gut 23 mast cells express hGIIA. However, there are no data on the expression and function of sPLA 2 s in mast cells purified ex vivo from human tissues. In this study we provide evidence that human lung mast cells (HLMCs) express mRNA for several sPLA 2 s and release a PLA 2 activity with biochemical and pharmacologic characteristics similar to that of the PLA 2 s secreted in the airways of patients with bronchial asthma.
METHODS Reagents
Percoll, dimethyl sulfoxide, L-glutamine, antibiotic-antimycotic solution (10,000 IU/mL penicillin, 10 mg/mL streptomycin, and 25 mg/mL amphotericin B), and phenylmethylsulfonyl fluoride (PMSF) were purchased from Sigma (St Louis, Mo). Dithiothreitol (DTT) was from MP Biomedicals (Solon, Calif). Me-Indoxam and AZ-1 were prepared as previously described. 11, 24 Tritiated oleic acid (OA)-labeled Escherichia coli membranes were kindly provided by Dr Gianfrancesco Goracci (University of Perugia, Perugia, Italy). The rabbit anti-human Fce antibody was donated by Drs T. Ishizaka and K. Ishizaka (La Jolla Institute for Allergy and Immunology, La Jolla, Calif).
Study population
Bronchoalveolar lavage was performed in 14 patients with mild persistent asthma and 19 nonasthmatic subjects (see the Methods section in this article's Online Repository at www.jacionline.org). The study protocol was approved by the Ethical Committee of the University of Naples Federico II, and informed consent was obtained from each subject before bronchoscopy.
Bronchoalveolar lavage procedure
Bronchoscopy and bronchoalveolar lavage were performed according to a standardized protocol based on current National Heart, Lung, and Blood Institute guidelines (see also the Methods section in this article's Online Repository). 25 
Cell isolation
The study protocol involving the use of human lung tissue was approved by the Ethical Committee of the University of Naples Federico II, and informed consent was obtained from patients undergoing thoracic surgery. Human mast cells were obtained from the lungs of patients undergoing thoracic surgery and were purified (>98%) by means of immunomagnetic selection, as previously described (see also the Methods section in this article's Online Repository). 26 
Cell incubation
Mast cells suspended in PCG buffer 26 (10 6 /mL) were incubated (at 378C for 15-120 minutes) with anti-IgE (0.03-1 mg/mL). For LTC 4 production, the cells (10 5 /mL) were preincubated (at 378C for 15 minutes) with increasing concentrations (0.01-10 mmol/L) of Me-Indoxam or AZ-1 before stimulation (at 378C for 30 minutes). The reactions were stopped by means of centrifugation (at 800g for 5 minutes at 48C), and the cell-free supernatant was stored at 2808C for determination of PLA 2 activity, histamine release, LTC 4 production, or b-hexosaminidase release. The cell pellets were lysed with freeze-thaw cycles in distilled water, and aliquots were stored at 2808C for determination of total content of histamine or b-hexosaminidase.
PLA 2 assay
PLA 2 activity in BALF and HLMC supernatants was measured as previously described 27 by using tritiated OA-labeled E coli membranes. PLA 2 activity was determined in 50 mmol/L Tris HCl (pH 7.5) and 10 mmol/L CaCl 2 in a total volume of 1.0 mL. The reaction was initiated by the addition of 0.1 mCi of tritiated OA-labeled E coli membranes. At the end of incubation (90 minutes at 378C), the reaction was stopped by adding 2 mL of methanol, 1 mL of chloroform, and 50 mL of 9% formic acid, and lipids were extracted and separated by means of thin-layer chromatography. Tritiated OA was measured by means of liquid scintillation counting (Tri-Carb 2800 TR; PerkinElmer, Waltham, Mass), and PLA 2 activity was expressed as picomoles of tritiated OA released per minute per milliliter of BALF or HLMC supernatants. Aliquots of BALF or HLMC supernatants were incubated (for 1 hour at 378C) with 10 mmol/L DTT, 10 mmol/L Me-Indoxam, 10 mmol/L AZ-1, or 2 mmol/L PMSF before PLA 2 assay to examine the effect of various inhibitors on PLA 2 activity.
Mediator release assays
Histamine was measured in duplicate determinations by using a commercially available enzyme immunoassay (Immunotech, Praha, Czech Republic). b-Hexosaminidase was measured in duplicate determinations by using a colorimetric assay. 28 LTC 4 was measured in mast cell supernatants in duplicate determinations with a commercially available enzyme immunoassay (GE Healthcare, Fairfield, Conn). The linearity range of this assay was 15 to 1,000 pg/mL. Inhibition of LTC 4 production was expressed as a percentage of maximum response calculated as follows: ðR2R b Þ=ðR max 2R b Þ3100, where R is the release in samples treated with the inhibitor, R b is the release in unstimulated samples, and R max is the release in samples stimulated in the absence of the inhibitor.
RT-PCR for sPLA 2 s
Total RNA from HLMCs was extracted by using the SV total RNA isolation system (Promega, Madison, Wis), treated with RNase-free DNase I, and suspended in diethylpyrocarbonate-treated (DEPC) water. RNA concentration and quality were assessed by means of spectroscopy. One microgram of total RNA was reverse transcribed with 25 mmol/L MgCl 2 , 50 mmol/L oligo(dT), and 200 U of Superscript III Reverse Transcriptase (Invitrogen, Carlsbad, Calif). Semiquantitative and real-time quantitative PCR (qPCR) were performed as previously described (see the Methods section and Table E1 in this article's Online Repository at www.jacionline.org).
29,30

Statistical analysis
Data are expressed as means 6 SEs of the indicated number of experiments. P values were determined with the Student unpaired or paired t tests. Correlation was assessed by using the linear regression function of Microsoft (Redmond, Wash) Excel software.
RESULTS
Characterization of PLA 2 activity in BALF
Initial experiments were performed to verify the presence of PLA 2 activity in the airways of patients with bronchial asthma. PLA 2 enzymatic activity was determined in the cell-free unconcentrated BALF of 14 asthmatic patients and 19 control subjects. Fig 1, A, shows that low levels of PLA 2 activity were found in the BALF of control subjects (9.3 6 0.9 pmol of tritiated OA/min/mL of BALF). PLA 2 activity was significantly increased in patients with asthma (28.3 6 2.2 pmol of tritiated OA/min/mL of BALF, P < .01 vs control subjects). There was no significant correlation between the PLA 2 activity and the protein content of the BALF of asthmatic patients (see Fig E1, A, in this article's Online Repository at www. jacionline.org), whereas a positive correlation was found in the control group (see Fig E1, B, in this article's Online Repository).
To verify that the activity detected in the airways of asthmatic patients was due to the presence of sPLA 2 s, we incubated the BALF with 2 different inhibitors of sPLA 2 s (DTT and MeIndoxam), 11 an inhibitor of cPLA 2 s (referred to as AZ-1), 31 or an inhibitor of platelet-activating factor acetylhydrolase (PMSF). 32 In particular, DTT is a reducing agent that alters the secondary structure of all sPLA 2 s by reducing disulfide bonds, whereas Me-Indoxam is an active, site-directed, reversible, competitive inhibitor of sPLA 2 enzymatic activity. 11 The latter compound binds to sPLA 2 catalytic sites, thereby preventing the interaction of the enzyme with its substrate. Because the various sPLA 2 isoforms display structural differences in their catalytic sites, 2 the affinity and inhibitory effect of Me-Indoxam are different for the various human sPLA 2 s. In particular, Me-Indoxam shows different potencies on the various sPLA 2 isoforms in in vitro assays with an inhibitory concentration of 50% (IC 50 ) of less than 100 nmol/L for hGIIA, hGIIE, and hGV; an IC 50 of between 200 and 600 nmol/L for hGIB and hGX; and an IC 50 of greater than 2 mmol/L for hGIID, hGIIF, hGIII, and hGXIIA.
11 Fig 1, B, shows that the PLA 2 activity in the BALF of asthmatic patients was almost completely suppressed by means of incubation with either DTT or Me-Indoxam, whereas it was not affected by AZ-1 or PMSF. These results indicate that 1 or more sPLA 2 s account for most of the enzymatic activity in the airways of asthmatic patients.
Release of sPLA 2 s from HLMCs
The detection of sPLA 2 activity in the airways of patients with asthma led us to investigate the role of lung mast cells as a potential source of these enzymes. In this group of experiments, we explored the capacity of primary human mast cells purified from the lung parenchyma (HLMCs) to release sPLA 2 activity on immunologic activation. Fig 2, A, shows that HLMCs spontaneously A, BALF from control subjects (n 5 19) and asthmatic patients (n 5 14) was assayed for PLA 2 activity, as described in the Methods section. Boxes indicate means 6 SEs. B, BALF was preincubated (for 1 hour at 378C) with 10 mmol/L DTT, 10 mmol/ L Me-Indoxam, 10 mmol/L AZ-1, or 2 mmol/L PMSF before the PLA 2 activity assay. Data are presented as means 6 SEs of BALF from 4 asthmatic patients. *P < .01 versus untreated.
released PLA 2 activity (23.6 6 2.4 pmol of tritiated OA/min/mL of HLMC supernatant). Stimulation of HLMCs with anti-IgE (0.03-1 mg/mL) concentration-dependently increased the release of PLA 2 activity, with a maximum at 1 mg/mL (75.6 6 5.7 pmol of tritiated OA/min/mL of HLMC supernatant). To understand whether the PLA 2 activity released by lung mast cells was from an sPLA 2 and had the same biochemical properties as those present in the BALF of asthmatic patients, supernatants of anti-IgEactivated HLMCs were preincubated with the PLA 2 inhibitors described in the previous section. Fig 2, B, shows that the PLA 2 activity released by HLMCs was completely blocked by the reducing agent DTT and by the site-directed sPLA 2 inhibitor Me-Indoxam at concentrations known to inhibit most of the human sPLA 2 s in vitro.
11 In contrast, AZ-1 and PMSF had no effect on PLA 2 activity released from mast cells. These data indicate that immunologically activated HLMCs released a PLA 2 activity with biochemical and pharmacologic properties of an sPLA 2 .
In the next group of experiments, we examined the kinetics of release of sPLA 2 activity and histamine from anti-IgE-stimulated HLMCs. In 3 different preparations of HLMCs, the release of the sPLA 2 activity was detectable already after 15 minutes of stimulation and peaked at 30 minutes (Fig 3, A) . The kinetics of sPLA 2 release were similar to those of histamine (half-time of sPLA 2 release, 15.3 6 3.2 minutes; half-time of histamine release, 12.8 6 2.6 minutes). Data obtained with HLMCs from 9 different donors indicated that there was a significant correlation between maximal release of sPLA 2 s (expressed as biologic activity) and of histamine (expressed as the percentage of the total cellular content) when mast cells were stimulated with an optimal concentration of anti-IgE (1 mg/mL; Fig 3, B) . These data suggest that the sPLA 2 is stored as a preformed mediator within mast cells and is rapidly released on immunologic activation.
Expression of mRNA for sPLA 2 s in HLMCs
The results obtained thus far have indicated that human mast cells release 1 or more isoforms of sPLA 2 s. We therefore examined constitutive gene expression of the known human isoforms of sPLA 2 s in resting HLMCs by means of RT-PCR by using target-specific primers for the various sPLA 2 s (see Table E1 in this article's Online Repository). Fig 4 shows the PCR amplification signals of 2 experiments representative of 4 different preparations of HLMCs. PCR fragments of the expected size encoding for hGIB (341 bp), hGIIA (434 bp), hGIID (294 bp), hGIIE (120 bp), hGIIF (211 bp), hGIII (500 bp), hGV (358 bp), hGX (370 bp), hGXIIA (105 bp), and hGXIIB (141 bp) were amplified in all HLMC preparations at subsaturating cycle numbers (35 cycles). As previously reported in human neutrophils, the primers used to evaluate hGV mRNA expression in HLMCs also generated a 251-bp PCR product that was identical to the A, HLMCs were incubated with or without anti-IgE (1 mg/mL). Histamine release and PLA 2 activity were determined in supernatants, as described in the Methods section. Data are presented as means 6 SEs of 4 experiments. *P < .01 versus unstimulated. B, HLMCs were incubated (for 30 minutes at 378C) with anti-IgE (1 mg/mL). Histamine release and PLA 2 activity were determined as described above. Correlation between histamine release and sPLA 2 activity was assessed by using the linear regression function of Microsoft Excel.
hGV mRNA from nucleotides 24 to 381 but lacked the untranslated region corresponding to exon 4. 24 These data indicate that primary HLMCs constitutively express mRNA for most human sPLA 2 s.
To investigate whether anti-IgE challenge of HLMCs modifies the expression of sPLA 2 s, we next examined mRNA for the major sPLA 2 isoforms (hGIIA, hGIID, hGIIE, hGIIF, hGIII, hGV, and hGX) in both resting and anti-IgE-activated HLMCs. To this end, we carried out qPCR in 3 different preparations of HLMCs incubated (at 378C for 3 hours) in the absence (unstimulated) or presence of anti-IgE (1 mg/mL). These experiments allowed an accurate quantification of the sPLA 2 s constitutively expressed by HLMCs. Table I shows that human mast cells express high levels of hGIII, hGV, and hGX; intermediate levels of hGIID and hGIIF; and low levels of hGIIA and hGIIE. Stimulation with anti-IgE did not enhance the expression of any sPLA 2 s examined. We rather observed a tendency toward a reduction in the expression of all sPLA 2 s, but these results did not reach statistical significance.
Role of endogenous sPLA 2 s in the generation of LTC 4 from HLMCs sPLA 2 s contribute to the generation of eicosanoids in murine mast cells 19, 27, 33, 34 and macrophages. 10, 35 However, it is still debated whether this contribution is due to intracellular or extracellular actions of sPLA 2 s. Our experiments demonstrated that human mast cells secrete 1 or more sPLA 2 s based on results obtained with Me-Indoxam. It is worth noting that, being cell impermeable, Me-Indoxam is able to inhibit the activity of sPLA 2 s only when they are secreted in the extracellular space. 36 Thus we were able to evaluate the role of endogenous PLA 2 s on LTC 4 production once these enzymes have been released by immunologically activated mast cells. In these experiments mast cells were stimulated with anti-IgE in the presence of increasing concentrations (0.1-10 mmol/L) of Me-Indoxam or AZ-1, a potent and cell-permeable inhibitor of GIV-cPLA 2 . At the end of incubation, LTC 4 production was determined in the supernatants. The cells were incubated (at 378C for 3 hours) in the absence (unstimulated) or presence of anti-IgE (1 mg/mL). At the end of incubation, mRNA expression of sPLA 2 s was evaluated as described above.
in mast cells is primarily due to the GIV-cPLA 2 . However, sPLA 2 s, once secreted, significantly contribute to this process by augmenting IgE-mediated cysteinyl LT production.
DISCUSSION
Patients with mild persistent asthma have higher levels of sPLA 2 activity in BALF than nonasthmatic control subjects. Primary lung mast cells constitutively express mRNA for several sPLA 2 s and release, on immunologic activation, sPLA 2 activity with biochemical characteristics similar to those of the sPLA 2 s detected in the BALF of asthmatic patients. Endogenous sPLA 2 s released by mast cells significantly contribute to IgE-mediated production of cysteinyl LTs.
Our results indicate that low levels of sPLA 2 s are detectable in the airways of control subjects and that this activity is increased in patients with mild asthma. A significant correlation between sPLA 2 activity and protein content exists in the BALF of control subjects. This correlation is lost in asthmatic patients, suggesting that sPLA 2 enzymes are selectively released in the airways of these patients. These results are in line with previous studies showing that bronchial antigen challenge in asthmatic patients increases sPLA 2 activity in the BALF 3-to 5-fold during the latephase reaction (ie, 4-20 hours after challenge). 5, 6 Several cells involved in the pathogenesis of asthma, including eosinophils, basophils, T H 2 cells, epithelial cells, macrophages, and fibroblasts, express sPLA 2 s. 20 Our work provides the first characterization of sPLA 2 s in human mast cells and indicates that they might be a source of these proinflammatory molecules in patients with asthma. An interesting observation of this study is that, in contrast to other inflammatory cells involved in asthma, mast cells not only express sPLA 2 s but also release 1 or more of these enzymes on stimulation. Epithelial cells, macrophages, and eosinophils in induced sputum of asthmatic patients express various sPLA 2 s 14 ; the ability of these cells to release sPLA 2 s was not investigated. This is a relevant issue because eosinophils, 37 basophils, 38 and macrophages 29 synthesize 1 or more sPLA 2 s but fail to release them, at least in vitro. Thus mast cells are rather unique among effector cells in bronchial asthma because they secrete sPLA 2 s when activated by IgE.
The release of sPLA 2 s from stimulated mast cells is rapid and coincident with that of histamine. However, stimulation with antiIgE does not modify the mRNA expression of any sPLA 2 s. These findings suggest that sPLA 2 s are synthesized and stored as preformed mediators. The correlation between the release of sPLA 2 activity and histamine by activated mast cells supports the hypothesis that these mediators are stored together within secretory granules. Early studies demonstrated that sPLA 2 s are contained within granules of rodent mast cells. 19, 39 Moreover, unpublished data from our laboratory also indicate that sPLA 2 s of the group II subfamily, identified by means of immunohistochemistry, colocalize with tryptase in skin mast cells from patients with mastocytosis.
Another unique feature of human mast cells is the expression of mRNA for a number of sPLA 2 s. This is at variance with most human inflammatory cells, which express a restricted profile of sPLA 2 isoforms. 20 The amount of mRNA for the various sPLA 2 s is rather different because HLMCs constitutively express high levels of hGIII, hGV, and hGX; medium levels of hGIID and hGIIF; and low levels of hGIIA and hGIIE. These results suggest that these cells might synthesize different quantities of the various sPLA 2 s. The detection of sPLA 2 proteins in mast cells by using conventional techniques (eg, Western blotting) is limited by the low number of cells retrieved from specimens of lung tissue. Thus although our data indicate that mast cells produce messages for all sPLA 2 s, they do not define which isoforms are translated into proteins, secreted, or both. However, information on the sPLA 2 s secreted by stimulated mast cells can be inferred from the data obtained with Me-Indoxam. This compound inhibits hGIB, hGIIA, hGIIE, hGV, and hGX with an IC 50 of less than 600 nmol/L and hGIID, hGIIF, hGIII, hGXIIA, and hGXIIB with an IC 50 of greater than 2 mmol/L. Thus it is conceivable that HLMC supernatants contain those sPLA 2 s that can be blocked by Me-Indoxam (hGIB, hGIIA, hGIIE, hGV, and hGX) rather than those sPLA 2 s that are poorly sensitive or nonsensitive to the inhibitory effect of this compound (hGIID, hGIIF, hGIII, hGXIIA, and hGXIIB). Further studies with more sensitive and specific techniques for sPLA 2 detection will define which sPLA 2 proteins are synthesized and released by human mast cells.
The role of sPLA 2 s in asthma is still under investigation. Some of these molecules, such as hGX, 9, 14 can participate in airway inflammation and remodeling through at least 3 mechanisms.
First, sPLA 2 s can contribute to prostaglandin and LT biosynthesis by potentiating the effect of cPLA 2 s. The results shown in Fig 5 indicate that LTC 4 production in stimulated HLMCs is primarily dependent on GIV-cPLA 2 . Nevertheless, the observation that the cell-impermeable sPLA 2 inhibitor Me-Indoxam reduces LTC 4 production by 40% indicates that the sPLA 2 s released by HLMCs contribute to LT production by cross-talking with GIV-cPLA 2 . These data are reminiscent of those obtained with murine mast cells and macrophages showing that sPLA 2 s alone do not initiate LTC 4 production but potentiate the eicosanoid-forming capacity of GIV-cPLA 2 . 27, 33, 35 The mechanisms of the cross-talk between cPLA 2 s and sPLA 2 s are still unclear, but it is currently believed that sPLA 2 -induced intracellular signals might increase the activation of the GIV-cPLA 2 .
34 Several isoforms of sPLA 2 s (GIB, GIIA, GV, and GX) bind to a specific M-type receptor, which generates intracellular signals leading to proinflammatory responses in target cells. 40 Me-Indoxam blocks not only the catalytic activity of sPLA 2 s 11 but also the receptor-mediated activation of inflammatory cells 30, 40 by preventing the binding of sPLA 2 s to the M-type receptor. 41 Of relevance to the present study, GIB, GIIA, and GV activate the M-type receptor expressed on murine BMMCs, thereby activating GIVcPLA 2 and promoting arachidonate mobilization and eicosanoid production. 42 Therefore the enhancement of LT production by sPLA 2 s in HLMCs might be due to an autocrine effect on the M-type receptor expressed on these cells.
A second mechanism by which sPLA 2 s might promote inflammation in asthma is through their nonenzymatic, receptor-mediated activation of inflammatory cells. 40 We and others demonstrated that several sPLA 2 s (GIB, GIIA, and GX) activate cytokine and chemokine production 30, [43] [44] [45] by interacting with the M-type or other receptors expressed on human inflammatory cells.
Finally, sPLA 2 s might contribute to the pathogenesis of asthma in vivo through the degradation of surfactant phospholipids. Alterations of the physicochemical properties of surfactant occur in asthma and are associated with airway obstruction and hyperreactivity. 46 sPLA 2 s hydrolyze surfactant phospholipids, generating lysophospholipids that, in turn, alter surfactant properties and induce proinflammatory effects. 47 Together, these observations help explain why knocking out just 1 sPLA 2 isoform (GX) dramatically reduces allergic inflammation. 9 The capacity of mast cells to secrete sPLA 2 s might also be relevant to the role of these cells in innate immunity.
16-18 Several sPLA 2 s have potent bactericidal activity. 48, 49 In addition, GIII sPLA 2 inhibits HIV replication by blocking viral entry into the cells. 50 Our results raise the interesting hypothesis that sPLA 2 s are mediators supporting the role of mast cells in innate immunity.
In conclusion, sPLA 2 s released by immunologically activated mast cells have biochemical properties similar to those of the enzymes secreted in the airways of asthmatic patients, indicating that mast cells might be a major source of sPLA 2 s in asthma. The demonstration that sPLA 2 s are released by mast cells further reinforces the concept that these molecules have an important role in inflammation and tissue remodeling in asthma.
METHODS
Study population
Fourteen patients (8 male and 6 female patients; age range, 20-54 years) were classified as having mild persistent asthma on the basis of clinical history and pulmonary function studies.
E1 All patients were atopic as documented by a positive skin test result for at least 1 aeroallergen. Inhaled corticosteroids were discontinued at least 4 weeks before bronchoscopy, and only short-acting b 2 -agonists on demand were allowed. As a control group, we enrolled patients (14 male and 5 female patients; age range, 18-60 years) with a single lung lesion in whom the BALF used for the experiments was obtained from the contralateral side. They had no history of atopic diseases and at the time of bronchoscopy were free of respiratory symptoms and had forced vital capacity and FEV 1 values of greater than 90% of the predicted value.
Bronchoalveolar lavage procedure
A flexible fiberoptic bronchoscope (Olympus BF type P20; Olympus, Center Valley, Pa) was wedged into a segmental or subsegmental bronchus, and 3 fractions (50 mL each) of saline preheated at 378C were introduced. Recovered fluid was pooled and filtered through 2 layers of sterile gauze. The fluid was then centrifuged twice at 800g for 10 minutes at 48C and stored at 2808C for determination of PLA 2 activity and total protein content by a Bradford-based assay (Bio-Rad, Hercules, Calif).
Purification of human lung mast cells
Lung fragments chopped with scissors were dispersed into their cellular elements by means of enzymatic digestion with pronase (Calbiochem, San Diego, Calif), chymopapain (Sigma), collagenase, and elastase (Calbiochem). The mast cell suspension was enriched (>80%) by means of flotation over Percoll (Sigma) density gradients and then purified by using positive immunomagnetic selection with the CD117 Microbead Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Mast cell numbers and purity were determined by means of toluidine blue staining. The purity of mast cells used in the experiments was always greater than 98%.
RT-PCR
For semiquantitative PCR, equivalent templates of cDNAs were amplified by using target-specific primers for hGIB, hGIIA, hGIID, hGIIE, hGIIF, hGIII, hGV, hGX, hGXIIA, hGXIIB, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; see Table E1 ). The PCR products were separated on 2% agarose gel, stained with ethidium bromide, and visualized by using the image analysis system ChemidocXRS (Bio-Rad).
Real-time quantitative PCR (qPCR) was performed on the iCycler (BioRad) with the Platinum SYBR Green qPCR kit (Invitrogen). Target-specific primers for hGIIA, hGIID, hGIIE, hGIIF, hGIII, hGV, hGX, and GAPDH suitable for qPCR were designed by using the Beacon Designer 3.0 (BioRad; see Table E1 ). After an initial denaturation step at 948C for 30 seconds, amplification was performed with 40 cycles of denaturation (948C) for 30 seconds, annealing (558C) for 30 seconds, and primer extension (728C). The data were analyzed with iCycler iQ analysis software (Bio-Rad), and the mRNA signals in each sample were normalized to that of the GAPDH mRNA. The quantification of the mRNA target was obtained by calculating the relative expression of the reference gene compared with GAPDH. Data were expressed as D cycle threshold (Ct), which was calculated as the number of PCR cycles for liftoff for the target mRNA of interest minus the number of PCR cycles for liftoff for GAPDH mRNA: DCt5Ct ðgene of interestÞ2Ct ðGAPDHÞ. The Ct values for GAPDH were typically around 23. A DCt of less than 10 means high to medium expression, a DCt of 10 to 15 means medium to low expression, and a DCt of greater than 15 means low expression. Cell-free BALF from patients with bronchial asthma (A; n 5 14) and control subjects (B; n 5 19) was assayed for PLA 2 activity by using tritiated OAlabeled E coli membranes, as described in the Methods section, and for total protein content by using a Bradford-based assay. Data are plotted as a function of PLA 2 activity versus protein content. Correlation was assessed by using the linear regression function of Microsoft Excel software.
